Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2026
Principal Business: Biopharmaceutical company developing cell therapies, specifically Deramiocel for Duchenne muscular dystrophy (DMD) cardiomyopathy.
Key Financial Metrics
This filing is a regulatory disclosure regarding a clinical/regulatory milestone and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Regulatory Status Update: The U.S. Food and Drug Administration (FDA) has lifted a previously issued Complete Response Letter (CRL) regarding the Company's Biologics License Application (BLA) for Deramiocel.
- Review Resumption: The FDA has resumed its review of the BLA seeking full approval for the treatment of DMD cardiomyopathy.
- Submission Classification: The submission is classified as a Class 2 resubmission.
Guidance, Outlook, and Risks
- PDUFA Target Date: A Prescription Drug User Fee Act (PDUFA) target action date has been established for August 22, 2026.
- Forward-Looking Statements: The filing includes statements regarding the BLA review and potential eligibility for a Priority Review Voucher (PRV).
- Risk Factors: Management cautions that actual results may differ materially from forward-looking statements due to known and unknown risks, referencing the "Risk Factors" section of the Annual Report on Form 10-K for the year ended December 31, 2024.
Investor Verification Checklist
- Verify the specific content of the press release attached as Exhibit 99.1 for detailed clinical data supporting the CRL lift.
- Confirm the definition and implications of a "Class 2 resubmission" for the Deramiocel BLA.
- Review the Company's most recent Form 10-K (year ended December 31, 2024) for updated risk factors and financial liquidity status.
- Monitor the August 22, 2026 PDUFA date for the final FDA action decision.